Company Overview and News

8
Movers and Shakers for Sept. 17

2018-09-17 biospace - 4
Let's take a look at some of the professionals moving to transition the pharma and biotech world this past week.
PIRS EYPT URGN SCMP ACHN NPSP

15
Why Is Mallinckrodt (MNK) Up 14.9% Since Last Earnings Report?

2018-09-06 zacks
A month has gone by since the last earnings report for Mallinckrodt (MNK - Free Report) . Shares have added about 14.9% in that time frame, outperforming the S&P 500.
KHC SCMP FOSL

4
Biotech Movers and Shakers Aug 20

2018-08-20 biospace
This past week’s roundup of Movers and Shakers in the biotech industry started with a surprise. Gilead Sciences' new(ish) chief medical officer was leaving the company six months after taking over the position.
ACAD CERC INOV GILD CERCZ SCMP CERCW

 
Mallinckrodt Is An Attractive Buy Opportunity In 2018

2018-08-17 seekingalpha
The year 2018 is turning out to be transformative for Mallinckrodt (MNK). In Q2 2018, the company reported $632 million worth sales, which was a 5% rise on a year-over-year or YoY basis. Non-GAAP EPS also rose from $1.36 in Q2 2017 to $1.78 in Q2 2018.
SCMP

11
Ironwood Pharmaceuticals' Proposed Separation Should Offer A Favorable Outcome For Shareholders

2018-08-17 seekingalpha - 1
Ironwood Pharmaceuticals is a commercial biotechnology company focused on the treatment of gastrointestinal diseases, abdominal pain, and gout.
IRWD SGYP BIIB AGN AZN SGYPW SCMP SNY

2
Mallinckrodt (MNK) Beats on Q2 Earnings and Sales, Ups View

2018-08-08 zacks
Shares of Mallinckrodt Public Limited Company (MNK - Free Report) are up 20.9% after the company reported strong results for the second quarter of 2018 and upped its annual guidance. Performance of hospital products especially Inomax and Ofirmev were impressive.
SGEN VRTX OAS BAX SCMP

4
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer

2018-08-08 globenewswire
Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization
IMMU URGN SCMP

15
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

2018-08-07 globenewswire - 1
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment of Peter Greenleaf to its Board of Directors. Mr. Greenleaf was elected to the Board at the Company’s annual stockholders meeting on July 10, 2018.
EYEG CERC CERCZ EYEGW SCMP BDSI CERCW

 
Cerecor Announces Expansion of Leadership Team

2018-07-16 globenewswire
BALTIMORE, July 16, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), today announced executive management changes that continue the Company’s strategic shift and further align its organizational structure to its long-term strategy. Specifically, effective today, the Company announced the appointment of Joe Miller as Chief Financial Officer, Dr. Pericles Calias as Chief Scientific Officer and Jamie Harrell as Executive Vice President of Marketing and Investor Relations.
CERC CERCZ SCMP CERCW

200
Mallinckrodt: The Cheapest Stock In Global Healthcare

2018-06-08 seekingalpha - 2
Contrary to shorts, Mallinckrodt is nowhere near bankruptcy and has nearly 4 years ahead without significant obligations.
VRX IPXL VRX MNK SCMP ENDP AMRX

50
BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board

2018-05-22 globenewswire
RALEIGH, N.C., May 22, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct offering of newly designated Series B Non-Voting Convertible Preferred Stock. The offering closed on May 21, 2018, yielding net proceeds of $48.9 million to BDSI.
CERC SCMP BDSI

1241
Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

2018-05-18 seekingalpha - 12
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
SNI BGX DISCB VST DISCA TSU TWX AU DISCK ENL BGLF STAY SHPG VIAB HAWK AABA DST OSG.WI SSNC AEM INSW AGG SYMX AET DISC FOX TMUSP TMUS RGORF VRX BKD UTX GOLD BX 2840 TWC OGISD NSW OGSRW MDT BGB SGYP SES CZR OGSWW OGISZ XLGLF SCMP QCOM INSW.WI FOXA OGSBW ENDP NMRK NXPI XL CTL RRS GLD AULGF OSG VRX MYL AGN ODP EGN MON SGYPW HZNP OSGB DISH OVSPW CACQ COL GOLD OVSPA OAS T OVSPD VSTE MNK THM

10
Harte Hanks to Appoint Four New Independent Directors to the Board

2018-05-17 globenewswire
SAN ANTONIO, May 17, 2018 (GLOBE NEWSWIRE) -- Harte Hanks (NYSE:HHS) today announced that it will appoint Timothy “Bant” Breen, Maureen O’Connell and Martin Reidy to its Board of Directors, effective June 15, 2018. Harte Hanks has accepted the resignations of current directors Christopher Harte, Scott Key and Judy Odom, also effective June 15, 2018. William F. Farley has also announced his resignation, to be effective upon appointment of a replacement.
HHS SCHL SCMP

14
BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business

2018-05-17 globenewswire
RALEIGH, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into an agreement with an affiliate of Broadfin Capital LLC (Broadfin), a large BDSI stockholder, to reconstitute BDSI’s Board of Directors and to significantly strengthen BDSI’s financial position. The closing of this agreement is subject to and effective upon the closing of BDSI’s $50 million equity financing announced earlier today.
MNK SCMP BDSI

314
Synergy Pharmaceuticals 'Evaluating All Options': Does That Mean A Formal Strategic Review?

2018-05-16 seekingalpha
2018 Q 1 Sales of Trulance missed analyst expectations, while Allergan reported an 8% increase in Linzess for the previous quarter.
IRWD SGYP AGN SGYPW SCMP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 864909106